Mary Pat Gallagher

Mary Pat Gallagher

Auto-generated profile, based on publicly available information

Mary Pat Gallagher

Pediatric Diabetes Center, NYU Langone Health, 135 East 31st Street, New York, NY 10016, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2012 in Clinical Pediatrics
Verified
Journal Article
Closed access
CBCarrie M. Bernstein
Carrie M. Bernstein
MSMelissa S. Stockwell
Melissa S. Stockwell
MGMary Pat Gallagher
Mary Pat Gallagher
SRSusan L. Rosenthal
Susan L. Rosenthal
KSKaren Soren
Karen Soren
Mental health comorbidities can negatively affect disease management in adolescents with chronic illnesses. This study sought to determine the prevalence and impact of mental health issues in a population of adolescents and young adults with type 1 diabetes. A cross-sectional study of 150 patients aged 11 to 25 years with type 1 diabetes from an urban, academic diabetes center was conducted. Participants completed 3 validated mental health disorder screening instruments: Beck’s Depression Inventory, the Screen for Child Anxiety Related Emotional Disorders-41 anxiety screen, and the Eating Disorder Screen for Primary Care. More than a third screened positive: 11.3% for depression, 21.3% for anxiety, and 20.7% for disordered eating (14.7% had ≥2 positive screens). Patients with a positive screen had twice the odds of having poor glycemic control as those without, as measured by HgbA1c. This study supports screening for mental health issues in adolescents and young adults with type 1 diabetes.

1 May 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CDCatherine Do
Catherine Do
CLCharles F. Lang
Charles F. Lang
JLJohn Lin
John Lin
HDHuferesh Darbary
Huferesh Darbary
IKIzabela Krupska
Izabela Krupska
BTBenjamin Tycko
Benjamin Tycko

5 June 2020 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
OEOsagie A. Ebekozien
Osagie A. Ebekozien
NNNudrat Noor
Nudrat Noor
MGMary Pat Gallagher
Mary Pat Gallagher
GAGuy Todd Alonso
Guy Todd Alonso

1 October 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HJHong Jiang
Hong Jiang
SCSteve M. Canfield
Steve M. Canfield
MGMary P. Gallagher
Mary P. Gallagher
HJHong H. Jiang
Hong H. Jiang
YJYihua Jiang
Yihua Jiang
LCLeonard Chess
Leonard Chess
A key feature of the immune system is its ability to discriminate self from nonself. Breakdown in any of the mechanisms that maintain unresponsiveness to self (a state known as self-tolerance) contributes to the development of autoimmune conditions. Recent studies in mice show that CD8+ T cells specific for the unconventional MHC class I molecule Qa-1 bound to peptides derived from the signal sequence of Hsp60 (Hsp60sp) contribute to self/nonself discrimination. However, it is unclear whether they exist in humans and play a role in human autoimmune diseases. Here we have shown that CD8+ T cells specific for Hsp60sp bound to HLA-E (the human homolog of Qa-1) exist and play an important role in maintaining peripheral self-tolerance by discriminating self from nonself in humans. Furthermore, in the majority of type 1 diabetes (T1D) patients tested, there was a specific defect in CD8+ T cell recognition of HLA-E/Hsp60sp, which was associated with failure of self/nonself discrimination. However, the defect in the CD8+ T cells from most of the T1D patients tested could be corrected in vitro by exposure to autologous immature DCs loaded with the Hsp60sp peptide. These data suggest that HLA-E–restricted CD8+ T cells may play an important role in keeping self-reactive T cells in check. Thus, correction of this defect could be a potentially effective and safe approach in the therapy of T1D.

24 June 2024 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MPMoshe Phillip
Moshe Phillip
PAPeter Achenbach
Peter Achenbach
AAAnanta Addala
Ananta Addala
AAAnastasia Albanese-O’neill
Anastasia Albanese-O’neill
TBTadej Battelino
Tadej Battelino
LDLinda DiMeglio
Linda DiMeglio
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programs are being increasingly emphasized. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody–positive (IAb+) children and adults who are at risk for (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in nonspecialized settings. To inform this monitoring, JDRF, in conjunction with international experts and societies, developed consensus guidance. Broad advice from this guidance includes the following: 1) partnerships should be fostered between endocrinologists and primary care providers to care for people who are IAb+; 2) when people who are IAb+ are initially identified, there is a need for confirmation using a second sample; 3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; 4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; 5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and 6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasizes significant unmet needs for further research on early-stage type 1 diabetes to increase the rigor of future recommendations and inform clinical care.

24 June 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
MPMoshe Phillip
Moshe Phillip
PAPeter Achenbach
Peter Achenbach
AAAnanta Addala
Ananta Addala
AAAnastasia Albanese-O’nEill
Anastasia Albanese-O’nEill
TBTadej Battelino
Tadej Battelino
LDLinda DiMeglio
Linda DiMeglio
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk of (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb+; (2) when people who are IAb+ are initially identified there is a need for confirmation using a second sample; (3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care. Graphical Abstract